Skip to content
Inciteful Med

Building Your Care Team: Hiring the Right Experts

Last updated:

Managing scleroderma requires a multidisciplinary medical team led by a specialized rheumatologist or dermatologist. Essential team members include a pulmonologist, cardiologist, gastroenterologist, and dentist. Seek care at a Scleroderma Center of Excellence for the best outcomes.

Key Takeaways

  • • A specialized rheumatologist should act as the 'quarterback' for managing systemic sclerosis, coordinating care among all your doctors.
  • • A complete scleroderma care team typically includes a pulmonologist, cardiologist, gastroenterologist, and a specialized dentist.
  • • Bring physical copies of your antibody panels, lung scans, and echocardiograms to your first specialist visit to ensure a productive appointment.
  • • Look for specialists who use the Modified Rodnan Skin Score (mRSS) to objectively track your skin changes at every visit.
  • • Seeking care at a Scleroderma Center of Excellence can provide access to advanced therapies and higher levels of medical expertise.

Because scleroderma is a complex, rare, and multi-system disease, it cannot be managed by a single doctor. You are essentially “hiring” a specialized medical team. To get the best outcomes, you need a team that communicates with each other, led by a “quarterback” who specializes in Systemic Sclerosis (SSc) or a Dermatologist for Morphea [1][2].

Your Multidisciplinary Care Team

A “complete” care team for scleroderma usually includes the following specialists [3][4][2]:

  • The Rheumatologist (The Quarterback): For systemic disease, this is your primary specialist. They should perform your Modified Rodnan Skin Score (mRSS) at every visit and coordinate with all other doctors [5][6].
  • The Dermatologist: Often the primary diagnosing and managing physician for Localized Scleroderma (Morphea). They coordinate treatments like UVA-1 phototherapy and topical management [7][8].
  • The Pulmonologist: Essential for managing Interstitial Lung Disease (ILD) and Pulmonary Arterial Hypertension (PAH), the two leading causes of serious complications [9][10].
  • The Cardiologist: Responsible for monitoring heart strain and high blood pressure in the lungs using specialized tools like the DETECT algorithm and echocardiograms [11][12].
  • The Gastroenterologist: Since GI issues (like reflux or bloating) affect nearly all patients, a GI specialist familiar with scleroderma-related motility issues is vital [3][13].
  • The Dentist: Scleroderma can cause microstomia (a smaller mouth opening) and dry mouth, which increases the risk of tooth decay. A dentist familiar with these challenges is a key part of your team [5][14].

Vetting Your Specialist

Not all rheumatologists are experts in scleroderma. Because the disease is so rare, many local doctors may only see a few cases a year [2]. When “interviewing” a new doctor, look for these signs of expertise:

  1. Standardized Testing: They should use the mRSS (a 17-point skin pinch test) to objectively track your disease [5][6].
  2. Subtype Classification: They should be able to clearly tell you if you have limited (lcSSc) or diffuse (dcSSc) cutaneous disease, as this determines your screening schedule [3][10].
  3. Center Affiliation: Expertise is often higher at a Scleroderma Center of Excellence, where doctors see hundreds of cases and participate in the latest clinical trials [15][16].

Preparing for Your First Visit

To make the most of your first consultation, you should bring physical copies (not just “the doctor has them”) of the following [17][18]:

  • Full Antibody Panel: Ensure you have the results for Anti-Scl-70 (ATA), Anticentromere (ACA), and Anti-RNA Polymerase III [19][20].
  • Imaging Reports and Disks: Bring the actual reports for your High-Resolution CT (HRCT) scan of the lungs and your Echocardiogram [10][18].
  • Pulmonary Function Tests (PFTs): Bring the full printout showing your FVC and DLCO numbers [18].
  • Nailfold Capillaroscopy Reports: If this microscopic exam of your cuticles has been done, the images or report are essential for staging your disease [21][17].

Having these records ready allows the specialist to spend their time examining you and creating a treatment plan, rather than hunting for old paperwork [18].

Frequently Asked Questions

What kind of doctor is the main specialist for systemic sclerosis?
For systemic scleroderma, a rheumatologist usually acts as the quarterback of your medical team. They coordinate your care with other specialists and track your disease progression using physical exams like the Modified Rodnan Skin Score.
Which specialists should be on my scleroderma care team?
A complete care team typically includes a rheumatologist, pulmonologist, cardiologist, gastroenterologist, and a dentist familiar with the condition. If you have localized scleroderma, also known as morphea, a dermatologist will often lead your care team.
What medical records should I bring to my first scleroderma appointment?
You should bring physical copies of your full antibody lab panel, High-Resolution CT lung scans, echocardiogram reports, and pulmonary function tests. Having these records ready helps your doctor create an immediate treatment plan rather than hunting for old paperwork.
What is a Scleroderma Center of Excellence?
A Scleroderma Center of Excellence is a specialized medical facility where doctors treat hundreds of cases and participate in the latest clinical trials. Receiving care or getting a second opinion at one of these centers provides access to top experts and advanced therapies.

Questions for Your Doctor

  • • How many patients with systemic sclerosis do you currently treat in your practice?
  • • Do you use the Modified Rodnan Skin Score (mRSS) at every visit to objectively track my skin thickening?
  • • Are you part of a multidisciplinary team that includes dedicated scleroderma-focused pulmonologists and cardiologists?
  • • If my disease progresses, do you have experience with advanced therapies like rituximab, tocilizumab, or referral for stem cell transplantation?
  • • What is your specific protocol for monitoring me for Scleroderma Renal Crisis (SRC), especially regarding blood pressure and steroid use?

Questions for You

  • • Who is the 'quarterback' of your medical team—the one doctor who sees all your test results and coordinates your care?
  • • Do you have a physical or digital folder containing your baseline scans (HRCT, Echo) and your full antibody lab panel?
  • • Are you experiencing difficulty opening your mouth wide (microstomia) or severe dry mouth that might require a specialized dentist?
  • • Have you checked if there is a 'Scleroderma Center of Excellence' within a reasonable driving distance for a second opinion or co-management?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Management of pregnancy with diffuse cutaneous systemic sclerosis: a case report and literature review.

    Yang L, Sun W, Yao Q

    The Journal of international medical research 2021; (49(11)):3000605211060160 doi:10.1177/03000605211060160.

    PMID: 34851779
  2. 2

    Caring for the Patient With Limited Systemic Scleroderma.

    Lachner KD

    Orthopedic nursing 2016; (35(1)):5-10; quiz 11-2 doi:10.1097/NOR.0000000000000212.

    PMID: 26814000
  3. 3

    Comprehensive description of the prevalence, serological and clinical characteristics, and visceral involvement of systemic sclerosis (scleroderma) in a large cohort from the United Arab Emirates Systemic Sclerosis Registry.

    Namas R, Elarabi M, Khan S, et al.

    Journal of scleroderma and related disorders 2023; (8(2)):137-150 doi:10.1177/23971983221145788.

    PMID: 37287950
  4. 4

    Therapeutic Approaches to Systemic Sclerosis: Recent Approvals and Future Candidate Therapies.

    Lescoat A, Roofeh D, Kuwana M, et al.

    Clinical reviews in allergy & immunology 2023; (64(3)):239-261 doi:10.1007/s12016-021-08891-0.

    PMID: 34468946
  5. 5

    Cutaneous Features, Autoantibody Profile, and Nailfold Capillaroscopy of Systemic Sclerosis: A Study of 60 Cases.

    Dave J, Mahajan S, Khadilkar P, Pradhan V

    The Journal of the Association of Physicians of India 2022; (70(11)):11-12 doi:10.5005/japi-11001-0136.

    PMID: 37355940
  6. 6

    Minimal Clinically Important Differences for the Modified Rodnan Skin Score: Results from the Scleroderma Lung Studies (SLS-I and SLS-II).

    Khanna D, Clements PJ, Volkmann ER, et al.

    Arthritis research & therapy 2019; (21(1)):23 doi:10.1186/s13075-019-1809-y.

    PMID: 30651141
  7. 7

    Effectiveness of PUVA vs. UVA1 phototherapy in the treatment of morphea patients.

    Malewska-Woźniak A, Osmola-Mañkowska A, Adamski Z

    Postepy dermatologii i alergologii 2022; (39(4)):757-761 doi:10.5114/ada.2021.108437.

    PMID: 36090739
  8. 8

    Morphea and Eosinophilic Fasciitis: An Update.

    Mertens JS, Seyger MMB, Thurlings RM, et al.

    American journal of clinical dermatology 2017; (18(4)):491-512 doi:10.1007/s40257-017-0269-x.

    PMID: 28303481
  9. 9

    Clinical features and prognostic factors of systemic sclerosis in Guangxi, China: Retrospective, single-center study of long-term survival in 470 patients.

    Chen J, Yang C, Pan J, et al.

    International journal of rheumatic diseases 2022; (25(2)):182-191 doi:10.1111/1756-185X.14261.

    PMID: 34889515
  10. 10

    Systemic Sclerosis and Pulmonary Disease.

    Ngo K

    Advances in experimental medicine and biology 2021; (1303()):173-182 doi:10.1007/978-3-030-63046-1_10.

    PMID: 33788193
  11. 11

    B-type Natriuretic Peptide as a Marker of Different Forms of Systemic Sclerosis.

    Nešković JS, Ristić A, Petronijević M, et al.

    Journal of medical biochemistry 2018; (37(4)):406-414 doi:10.1515/jomb-2017-0058.

    PMID: 30584399
  12. 12

    Pulmonary hypertension in connective tissue diseases: an update.

    Aithala R, Alex AG, Danda D

    International journal of rheumatic diseases 2017; (20(1)):5-24 doi:10.1111/1756-185X.13001.

    PMID: 28205373
  13. 13

    Circulating Galectin-1 and Galectin-3 in Sera From Patients With Systemic Sclerosis: Associations With Clinical Features and Treatment.

    Sundblad V, Gomez RA, Stupirski JC, et al.

    Frontiers in pharmacology 2021; (12()):650605 doi:10.3389/fphar.2021.650605.

    PMID: 33959016
  14. 14

    Assessment of Central Corneal Thickness in Different Subtypes of Systemic Sclerosis.

    Gomes BA, Santhiago MR, Kara-Junior N, et al.

    Ocular immunology and inflammation 2016; (24(6)):693-698 doi:10.3109/09273948.2015.1076008.

    PMID: 26652214
  15. 15

    New promising drugs for the treatment of systemic sclerosis: pathogenic considerations, enhanced classifications, and personalized medicine.

    Lescoat A, Varga J, Matucci-Cerinic M, Khanna D

    Expert opinion on investigational drugs 2021; (30(6)):635-652 doi:10.1080/13543784.2021.1923693.

    PMID: 33909517
  16. 16

    Collaborative National Quality and Efficacy Registry (CONQUER) for Scleroderma: outcomes from a multicenter US-based systemic sclerosis registry.

    Shanmugam VK, Frech TM, Steen VD, et al.

    Clinical rheumatology 2020; (39(1)):93-102 doi:10.1007/s10067-019-04792-y.

    PMID: 31667644
  17. 17

    Chronic dyspnea with Raynaud's phenomenon and elevated ANA: A diagnosis of systemic sclerosis sine scleroderma.

    Chong WH, Saha BK, Beegle S

    The American journal of the medical sciences 2023; (365(2)):198-204 doi:10.1016/j.amjms.2022.01.023.

    PMID: 35276077
  18. 18

    Sarcopenia in systemic sclerosis: the impact of nutritional, clinical, and laboratory features.

    Corallo C, Fioravanti A, Tenti S, et al.

    Rheumatology international 2019; (39(10)):1767-1775 doi:10.1007/s00296-019-04401-w.

    PMID: 31372720
  19. 19

    Serodiscordant patients with systemic sclerosis: when antibody does not correspond to skin involvement.

    Iniesta Arandia N, Espinosa G, Tolosa Vilella C, et al.

    Clinical and experimental rheumatology 2020; (38 Suppl 125(3)):106-114.

    PMID: 31969223
  20. 20

    Clinical significance of autoantibodies in dermatomyositis and systemic sclerosis.

    Tartar DM, Chung L, Fiorentino DF

    Clinics in dermatology 2018; (36(4)):508-524 doi:10.1016/j.clindermatol.2018.04.008.

    PMID: 30047434
  21. 21

    Copeptin as a Biomarker of Microcirculation Alterations in Systemic Sclerosis.

    Maciejewska M, Stec A, Zaremba M, et al.

    Clinical, cosmetic and investigational dermatology 2023; (16()):1351-1361 doi:10.2147/CCID.S409490.

    PMID: 37255624

This guide on building a scleroderma care team is for educational purposes only. Always consult your rheumatologist or primary care physician for personalized medical advice and treatment coordination.

Stay up to date

Get notified when new research about Scleroderma is published.

No spam. Unsubscribe anytime.